Cyclerion Therapeutics, Inc. (KRSA) fundamentals score
Over the past year, Cyclerion Therapeutics has refined its strategic direction toward programs that combine established pharmacologic agents with enabling technologies designed to improve precision, reproducibility, and patient outcomes. As part of this strategy, Cyclerion has evaluated multiple opportunities and prioritized CYC-126, an individualized therapy for TRD as its foundational development program.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 2.5 out of 10, Unhealthy fundamentals
- Growth: 1.3/10
- Profitability: 1.0/10
- Financial health: 4.4/10
- Earnings quality: 5.5/10
- Valuation: 1.5/10
Scores are calculated from Cyclerion Therapeutics, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10